삼양바이오팜

0120G0KOSPI

46.5 / 100

Reference Date: 2026-10-23

Financial Score19.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 7.9% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Samyang Biopharm operates in three main business segments: medical devices, pharmaceuticals, and new drug development. Key products include biodegradable surgical sutures and hemostatic agents in the medical device sector, and anticancer drugs for solid and blood cancers in the pharmaceutical sector. The company is developing gene therapy platforms (SENS) for new drug research, with medical devices contributing 62.5% of total revenue.

Number of Employees

407people

Average Salary

79.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

143.63Industry Average 15.000.0Point

9.6x industry avg (risky)

PBR

1.37Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

—Industry Average 8.003.5Point

Debt Ratio

1.29Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 5.0 / 10 points

Revenue Growth Rate

1.5 / 3

Operating Profit Growth Rate

1.5 / 3

ROE Trend

2.0 / 4

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (11%, downtrend)

Current 43,200Won52-week high 142,70052-week low 30,200

1-month return1.0Point

1m -7.89% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0